"The US Food and Drug Administration (FDA) has approved an extended-release capsule formulation of carbidopa-levodopa (Rytary, IPX066, Impax Pharmaceuticals) for the treatment of Parkinson's disease (PD), postencephalitic parkinsonism, an"...
Benztropine Mesylate Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Benztropine mesylate is used as an adjunct treatment in the therapy of all forms of Parkinsonism. It is also used to help control extrapyramidal disorders, which are side effects that may result from taking anti-psychotic medications. It is an anti-Parkinson's agent and anticholinergic agent. This medication is available in generic form. Common side effects include rapid heart rate, constipation, vomiting, nausea, dry mouth, confusion, visual hallucinations, nervousness, depression, blurred vision, or problems with urination.
To treat Parkinson's disease, the usual daily dose of benztropine mesylate is 1 to 2 mg, with a range of 0.5 to 6 mg orally or parenterally. In treating extrapyramidal disorders due to neuroleptic drugs (e.g., phenothiazines), the recommended dosage is 1 to 4 mg once or twice a day orally or parenterally. Benztropine mesylate may interact with antipsychotic drugs, or antidepressants. Tell your doctor all medications and supplements you use. Safe use in pregnancy has not been established. Consult your doctor before breastfeeding.
Our benztropine mesylate Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Benztropine Mesylate FDA Prescribing Information: Side Effects
The adverse reactions below, most of which are antichlolinergic in nature, have been reported and within each category are listed in order of decreasing severity.
If dry mouth is so severe that there is difficulty in swallowing or speaking, or loss of appetite and weight, reduce dosage, or discontinue the drug temporarily.
Slight reduction in dosage may control nausea and still give sufficient relief of symptoms. Vomiting may be controlled by temporary discontinuation, followed by resumption at a lower dosage.
Toxic psychosis, including confusion, disorientation, memory impairment, visual hallucinations; exacerbation of pre-existing psychotic symptoms; nervousness; depression; listlessness; numbness of fingers.
Blurred vision, dilated pupils.
Urinary retention, dysuria.
Metabolic/Immune or Skin
Read the entire FDA prescribing information for Benztropine Mesylate (Benztropine Mesylate)
Additional Benztropine Mesylate Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.